QLT INC (QLTI) Upgraded by Zacks to OUTPERFORM

Zacks Zacks Investment Research upgraded shares of QLT INC (QLTI) from NEUTRAL to OUTPERFORM on February 26, 2013, with a target price of $8.70.

QLT PhotoTherapeutics Inc. is engaged in the development and commercialization of proprietary pharmaceutical products for use in photodynamic therapy, an emerging field of medicine utilizing light-activated drugs in the treatment of disease. QLT's innovative science has advanced photodynamic therapy beyond applications in cancer towards potential breakthrough treatments in ophthalmology and autoimmune disease. QLT PhotoTherapeutics Inc. is headquartered in Vancouver, Canada.

Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.

To get a free copy of the research report on QLT INC (QLTI),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .

Be the first to comment

Leave a Reply